Abstract:Abstract Huntington's disease (HD) is a gradually severe neurodegenerative ailment characterised by an increase of a specific trinucleotide repeat sequence (cytosine–adenine–guanine, CAG). It is passed down as a dominant characteristic that worsens over time, creating a significant risk. Despite being monogenetic, the underlying mechanisms as well as biomarkers remain poorly understood. Furthermore, early detection of HD is challenging, and the available diagnostic procedures have low precision and accuracy. The research was conducted to provide knowledge of the biomarkers, pathways and therapeutic targets involved in the molecular processes of HD using informatic based analysis and applying network‐based systems biology approaches. The gene expression profile datasets GSE97100 and GSE74201 relevant to HD were studied. As a consequence, 46 differentially expressed genes (DEGs) were identified. 10 hub genes ( TPM1 , EIF2S3 , CCN2 , ACTN1 , ACTG2 , CCN1 , CSRP1 , EIF1AX , BEX2 and TCEAL5 ) were further differentiated in the protein–protein interaction (PPI) network. These hub genes were typically down‐regulated. Additionally, DEGs‐transcription factors (TFs) connections (e.g. GATA2, YY1 and FOXC1), DEG‐microRNA (miRNA) interactions (e.g. hsa‐miR‐124‐3p and has‐miR‐26b‐5p) were also comprehensively forecast. Additionally, related gene ontology concepts (e.g. sequence‐specific DNA binding and TF activity) connected to DEGs in HD were identified using gene set enrichment analysis (GSEA). Finally, in silico drug design was employed to find candidate drugs for the treatment HD, and while the possible modest therapeutic compounds (e.g. cortistatin A, 13,16‐Epoxy‐25‐hydroxy‐17‐cheilanthen‐19,25‐olide, Hecogenin) against HD were expected. Consequently, the results from this study may give researchers useful resources for the experimental validation of Huntington's diagnosis and therapeutic approaches.

Integrated analysis on transcriptome and behaviors defines HTT repeat-dependent network modules in Huntington's disease

Beyond CAG Repeats: The Multifaceted Role of Genetics in Huntington Disease

Progress in studies of gene therapy for Huntington's disease

Ccg Polymorphisms in the Huntingtin Gene Have No Effect on the Pathogenesis of Patients with Huntington'S Disease in Mainland Chinese Families

Longitudinal Transcriptomic Dysregulation in the Peripheral Blood of Transgenic Huntington’s Disease Monkeys

Identification of genetic modifiers of Huntington's disease somatic CAG repeat instability by in vivo CRISPR-Cas9 genome editing

Msh3 and Pms1 Set Neuronal CAG-repeat Migration Rate to Drive Selective Striatal and Cortical Pathogenesis in HD Mice

Identification of key genes and signaling pathway in the pathogenesis of Huntington's disease via bioinformatics and next generation sequencing data analysis

Clinical and Genetic Profiles in Chinese Patients with Huntington's Disease: A Ten-year Multicenter Study in China.

Identification of genetic modifiers of Huntington′s disease somatic CAG repeat instability by in vivo CRISPR-Cas9 genome editing

Functional Characterisation of the Circular RNA, circHTT(2-6), in Huntington's Disease

Long somatic DNA-repeat expansion drives neurodegeneration in Huntington disease

Identification of molecular targets and small drug candidates for Huntington's disease via bioinformatics and a network‐based screening approach

Clinical Characteristics of Huntington Disease in Two Pedigrees and Analysis of Expanded CAG Trinucleotide Repeat

HAP40 Modulates Mutant Huntingtin Aggregation and Toxicity in Huntington’s Disease Mice

Modulating glial genes involved in synaptic function mitigates pathogenesis and behavioral deficits in a<i>Drosophila</i>model of Huntington’s Disease

Huntingtin Interacting Proteins and Pathological Implications

Genetic modifiers of somatic expansion and clinical phenotypes in Huntington's disease reveal shared and tissue-specific effects

Metabolic disruption identified in the Huntington’s disease transgenic sheep model

Latest Advances on New Promising Molecular-Based Therapeutic Approaches for Huntington’s Disease

Lack of RAN-mediated Toxicity in Huntington's Disease Knock-in Mice.